Detection of Postcolonoscopy Colorectal Neoplasia by Multi-target Stool DNA.
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
18 06 2021
18 06 2021
Historique:
received:
27
01
2021
accepted:
20
05
2021
entrez:
18
6
2021
pubmed:
19
6
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Significant variability between colonoscopy operators contributes to postcolonoscopy colorectal cancers (CRCs). We aimed to estimate postcolonoscopy colorectal neoplasia (CRN) detection by multi-target stool DNA (mt-sDNA), which has not previously been studied for this purpose. In a retrospective cohort of patients with +mt-sDNA and completed follow-up colonoscopy, positive predictive value (PPV) for endpoints of any CRN, advanced adenoma, right-sided neoplasia, sessile serrated polyps (SSP), and CRC were stratified by the time since previous colonoscopy (0-9, 10, and ≥11 years). mt-sDNA PPV at ≤9 years from previous average-risk screening colonoscopy was used to estimate CRN missed at previous screening colonoscopy. Among the 850 studied patients with +mt-sDNA after a previous negative screening colonoscopy, any CRN was found in 535 (PPV 63%). Among 107 average-risk patients having +mt-sDNA ≤9 years after last negative colonoscopy, any CRN was found in 67 (PPV 63%), advanced neoplasia in 16 (PPV 15%), right-sided CRN in 48 (PPV 46%), and SSP in 20 (PPV 19%). These rates were similar to those in 47 additional average risk persons with previous incomplete colonoscopy and in an additional 68 persons at increased CRC risk. One CRC (stage I) was found in an average risk patient who was mt-sDNA positive 6 years after negative screening colonoscopy. The high PPV of mt-sDNA 0-9 years after a negative screening colonoscopy suggests that lesions were likely missed on previous examination or may have arisen de novo. mt-sDNA as an interval test after negative screening colonoscopy warrants further study.
Identifiants
pubmed: 34140458
doi: 10.14309/ctg.0000000000000375
pii: 01720094-202106000-00011
pmc: PMC8216679
doi:
Substances chimiques
DNA, Neoplasm
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00375Subventions
Organisme : NCI NIH HHS
ID : R37 CA214679
Pays : United States
Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2016;315:2564–75.
Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: Updated evidence report and systematic review for the us preventive services task force. JAMA 2016;315:2576–94.
Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Gastrointest Endosc 2015;81:31–53.
Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095–105.
Jensen CE, Villanueva JY, Loaiza-Bonilla A. Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma. J Gastrointest Oncol 2018;9:778–84.
Lim DR, Kuk JK, Kim T, et al. Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection: Which side is better outcome? Medicine (Baltimore) 2017;96:e8241.
Shin JG, Kim HW, Park SB, et al. Polyp missing rate and its associated risk factors of referring hospitals for endoscopic resection of advanced colorectal neoplasia. Medicine 2017;96:e6742.
Fischbach W, Elsome R, Amlani B. Characteristics of right-sided colonic neoplasia and colonoscopy barriers limiting their early detection and prognosis: A review of the literature. Expert Rev Gastroenterol Hepatol 2018;12:585–96.
Crockett SD, Snover DC, Ahnen DJ, et al. Sessile serrated adenomas: An evidence-based guide to management. Clin Gastroenterol Hepatol 2015;13:11–26.e1.
Rabeneck L, Paszat LF. Circumstances in which colonoscopy misses cancer. Frontline Gastroenterol 2010;1:52–8.
Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370:1298–306.
O'Connell BM, Crockett SD. The clinical impact of serrated colorectal polyps. Clin Epidemiol 2017;9:113–25.
Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010;362:1795–803.
Baxter NN, Warren JL, Barrett MJ, et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol 2012;30:2664–9.
Stegmaier C, Brenner H, Altenhofen L, et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: Population-based study. J Natl Cancer Inst 2010;102:89–95.
Senore C, Bellisario C, Segnan N. Distribution of colorectal polyps: Implications for screening. Best Pract Res Clin Gastroenterol 2017;31:481–8.
Guo CG, Zhang F, Ji R, et al. Efficacy of segmental re-examination of proximal colon for adenoma detection during colonoscopy: A randomized controlled trial. Endoscopy 2017;49:243–50.
Chen S, Sun K, Chao K, et al. Detection rate and proximal shift tendency of adenomas and serrated polyps: A retrospective study of 62,560 colonoscopies. Int J Colorectal Dis 2018;33:131–9.
Lee JK, Jensen CD, Levin TR, et al. Long-term risk of colorectal cancer and related deaths after a colonoscopy with normal findings. JAMA Intern Med 2019;179:153–60.
Pilonis ND, Bugajski M, Wieszczy P, et al. Long-term colorectal cancer incidence and mortality after a single negative screening colonoscopy. Ann Intern Med 2020;173:81–91.
Robertson DJ, Lieberman DA, Winawer SJ, et al. Colorectal cancers soon after colonoscopy: A pooled multicohort analysis. Gut 2014;63:949–56.
Pohl H, Robertson DJ. Colorectal cancers detected after colonoscopy frequently result from missed lesions. Clin Gastroenterol Hepatol 2010;8:858–64.
Zhao S, Wang S, Pan P, et al. Magnitude, risk factors, and factors associated with adenoma miss rate of tandem colonoscopy: A systematic review and meta-analysis. Gastroenterology 2019;156:1661–74.e11.
Knudsen AB, Hur C, Gazelle GS, et al. Rescreening of persons with a negative colonoscopy result: Results from a microsimulation model. Ann Intern Med 2012;157:611–20.
Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol 2013;11:1313–8.
Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370:1287–97.
Johnson DH, Kisiel JB, Burger KN, et al. Multitarget stool DNA test: Clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. Gastrointest Endosc 2017;85:657–65.e1.
Cubiella J, Castells A, Andreu M, et al. Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs. United European Gastroenterol J 2017;5:255–60.
Wong JCT, Chiu HM, Kim HS, et al. Adenoma detection rates in colonoscopies for positive fecal immunochemical tests versus direct screening colonoscopies. Gastrointest Endosc 2019;89:607–13.e1.
Eckmann JD, Ebner DW, Bering J, et al. Multitarget stool DNA screening in clinical practice: High positive predictive value for colorectal neoplasia regardless of exposure to previous colonoscopy. Am J Gastroenterol 2020;115:608–15.
Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc 2020;91:463–85.e5.
Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143:844–57.
Sim JS, Koo JS. Predictors of inadequate bowel preparation and salvage options on colonoscopy. Clin Endosc 2016;49:346–9.
Pasha SF. Applications of colon capsule endoscopy. Curr Gastroenterol Rep 2018;20:22.
PASS 2020 Power Analysis and Sample Size Software. NCSS, LLC: Kaysville, UT, 2020.
Lieberman DA, Holub JL, Moravec MD, et al. Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA 2008;300:1417–22.
Kim NH, Jung YS, Lim JW, et al. Yield of repeat colonoscopy in asymptomatic individuals with a positive fecal immunochemical test and recent colonoscopy. Gastrointest Endosc 2019;89:1037–43.
Redwood DG, Asay ED, Blake ID, et al. Stool DNA testing for screening detection of colorectal neoplasia in Alaska native people. Mayo Clin Proc 2016;91:61–70.
Bosch LJW, Melotte V, Mongera S, et al. Multitarget stool DNA test performance in an average-risk colorectal cancer screening population. Am J Gastroenterol 2019;114:1909–18.
Heigh RI, Yab TC, Taylor WR, et al. Detection of colorectal serrated polyps by stool DNA testing: Comparison with fecal immunochemical testing for occult blood (FIT). PLoS One 2014;9:e85659.
Gachabayov M, Lebovics E, Rojas A, et al. Performance evaluation of stool DNA methylation tests in colorectal cancer screening: A systematic review and meta-analysis. Colorectal Dis 2021;23:1030–42.
Wang J, Liu S, Wang H, et al. Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: A multicenter clinical study. Clin Epigenetics 2020;12:162.
Su WC, Kao WY, Chang TK, et al. Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer. Biosci Rep 2021;41:BSR20201930.
Sawhney MS, Farrar WD, Gudiseva S, et al. Microsatellite instability in interval colon cancers. Gastroenterology 2006;131:1700–5.
Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology 2013;144:74–80.e1.
Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2020;115:415–34.
Berger BM, Schroy PC III, Dinh TA. Screening for colorectal cancer using a multitarget stool DNA test: Modeling the effect of the intertest interval on clinical effectiveness. Clin Colorectal Cancer 2016;15:e65–74.
Ladabaum U, Mannalithara A. Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia. Gastroenterology 2016;151:427–39.e6.
Piscitello A, Saoud L, Fendrick AM, et al. Mo1598 estimating the impact of imperfect adherence to stool-based colorectal cancer screening strategies on comparative effectiveness using the RCR-AIM microsimulation model. Gastroenterology 2020;158:S-910.
Fisher DA, Saoud L, Hassmiller Lich K, et al. Impact of screening and follow-up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRC-AIM microsimulation model. Cancer Med 2021;10:2855–64.